Myriad genetics®

Second Quarter 2026 Earnings Call

July 30, 2026

Forward-looking statements and Non-GAAP financial measures

Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company.

FORWARD-LOOKING STATEMENTS AND DISCLAIMERS

These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or other forward-looking statements. All third-party marks—® and ™—are the property of their respective owners. Certain market and industry data has been obtained from third-party sources, which the Company believes are reliable, but the Company has not independently verified the information provided by third-party sources. Unless otherwise noted, market growth rates used in this presentation are estimates based on Company and third-party industry research.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. Definitions of the non-GAAP financial measures and a reconciliation of the GAAP to non-GAAP financial results are provided in the Appendix to this presentation.

The Company does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the Company's control, or cannot be reasonably predicted at the time of this presentation. Such adjustments include, but are not limited to, strategic realignment, costs related to amortization of intangibles from acquisitions, impairment and related charges, depreciation, equity compensation, tax benefits, and other adjustments. For example, stock-based compensation may fluctuate based on the timing of employee stock transactions and unpredictable fluctuations in the Company's stock price. Any associated estimate of these items and their impact on GAAP performance could vary materially.

Second quarter 2026 performance

New initiatives focused on driving increased efficiency, productivity and scalability

- Q2'26 revenue down 11% YOY reflecting 1% YOY decline in volume and 9% YOY decrease in average revenue per test
- Payer friction elevated in Q2'26; executing a comprehensive multi-quarter initiative to mitigate reimbursement pressure
- Positive demand in CCC continues with strong Q2'26 volume growth, Prolaris+AI launch, and Precise MRD MolDX submission
- Activated Ascend initiative to increase organizational efficiency, productivity, and scalability

Updating FY 2026 financial guidance

FY 2026	CURRENT	PRIOR
Revenue	$770M - $790M	$860M - $880M
Adj gross margin	66% - 67%	68% - 69%

Comprehensive initiative to mitigate MyRisk reimbursement pressure

Situation

Payer dynamics: heightened focus on utilization management, but no change in medical policy.

The effect: more prior authorization requirements, added medical records requests, and higher denial rates.

Optimizing end-to-end revenue cycle process

Enhancing front-end coverage verification and prior authorization workflows

Increasing alignment of services with payer expectations

Increasing utilization of Artificial Intelligence

Deploying AI-enabled workflows for medical record retrieval, denial triage, payer response management

Engaging in a policy-based approach

Better align medical policy with clinical practice and the utilization of our services

On-track with key 2026 product publications, submissions and launches

HCT

- Launched MyRisk Disease Specific Panels; H1‘26
- Increase sample volume growth rate

Prostate Cancer

- Launched Prolaris + AI test; Q2’26
- Prolaris meta-analysis publication published; July'26

Precise MRD

- Initiated commercial testing for select customers; March‘26
- MolDX submission for Breast; July'26
- Breast publication; MONITOR study published; Q2’26
- MolDx submissions for Renal and CRC; H2’26E
- CRC data publication, MONSTAR3 study; H2’26E

Prenatal Health

- Reported out on FirstGene CONNECTOR study; H1‘26
- Commercial launch of FirstGene; July'26

Cancer Care Continuum

- Focus on increasing sample volume growth
- Expect to add new strategic partnerships as part of growth plan

Strengthening Myriad

- Increase focus on Cancer Care Continuum
- Increase org efficiency, productivity, and scalability
- Mitigate payer friction
- Evaluate product portfolio rigorously

Strengthens

- Growth
- Profitability
- Predictability

Taking important actions to better position Myriad to drive accelerated profitable growth

Business Update

Brian Donnelly

CHIEF COMMERCIAL OFFICER

Continue to drive strong Hereditary Cancer test volume growth

Second quarter 2026 and recent highlights

- Hereditary cancer testing 8% YOY volume growth in Q2'26
- Highest volume quarter for unaffected HCT in last three years
- Prolaris+AI launched Q2'26; positive feedback
- Precise MRD momentum building; expanded clinical testing in Q2'26
- Submitted Precise MRD first breast cancer indication to MolDX program to establish coverage and reimbursement

Operational results:

$114M
Q2'26 revenue

~95K
Q2'26 volume

Key performance indicators:

Hereditary Cancer

8%
Volume growth[1]

(13)%
Revenue growth[1]

1: Q2'26 Growth YOY

Moving forward with FirstGene launch amidst slower prenatal recovery

Second quarter 2026 and recent highlights

- Launched FirstGene multi-prenatal screen; July'26
- FirstGene CONNECTOR study enrollment momentum continued; expected completion of enrollment in H2‘26

Operational results:

$40M
Q2‘26 revenue

~144K
Q2‘26 volume

Key business indicators:

Prenatal

(9)%	(16)%
Volume growth[1]	Revenue growth[1]

1: Q2‘26 Growth YOY

Maintaining leadership with disciplined level of investment and focus

Second quarter 2026 and recent highlights

- 40K+ clinicians ordered GeneSight in Q2‘26
- Maintaining focus on expanding coverage and go-to-market strategies
- GeneSight average revenue per test in Q2’26 includes a write-off of aged receivables

Operational results:

$37M
Q2‘26 revenue

~140K
Q2‘26 volume

Key performance indicators:

GeneSight

4%	(3)%
Volume growth[1]	Revenue growth[1]

1: Q2‘26 Growth YOY

Financial Update

Ben Wheeler

CHIEF FINANCIAL OFFICER

Second quarter 2026 performance and takeaways

Q2'26 reflects meaningful CCC volume growth offset by payer friction and Prenatal

Q2‘26 revenue of $190.7M, or (11)% YOY, reflects:

Test volume trend (YOY) in:

- Cancer Care Continuum: 6%
- Mental Health: 4%
- Prenatal Health: (9)%

Average revenue per test changes (YOY) in:

- Cancer Care Continuum: (15)%
- Mental Health: (6)%
- Prenatal Health: (8)%

Solid balance sheet continues to support investment levels

66.6% gross margins in Q2‘26

Q2‘26 adj operating expense* increased $6.7M YOY and reflects commercial growth investments

$(16.9M) adj EBITDA* and $(0.25) adj EPS* in Q2‘26

Liquidity position: Access to ~$190M at end of Q2‘26

Taking action to unlock value; Reset 2026 guidance

Activated initiatives to increase organizational efficiency, productivity, and scalability; Q2’26

Resetting 2026 guidance due to:

- Q2 results and reduced estimates for Prenatal Health, average revenue per test

*GAAP to non-GAAP reconciliations for Q2‘26 can be found in the Appendix

A deeper dive into average revenue per test trends

Hereditary Cancer Test (HCT)

(2)% Average annual change in revenue per test over last 3 years*



Key takeaways:

- (2)% annual change in avg revenue per HCT test over 2023 – 2026
- $1,100 - $1,250 range of avg revenue per HCT test (Q3’22 – Q1’26)
- Q2’26 impacted by outsized prior-period collection adjustment recognized in the quarter

Comprehensive action plan

RCM improvements

Optimizing workflows to accelerate cash collections and improve predictability

Team investments

Building on past investments in team capabilities and tools to increase precision in claim processing

Ongoing 3rd party engagement

Advancing reimbursement stability through payer engagement, LBM collaboration, and policy advocacy

*Change in average annual revenue per HCT test utilizes average trailing twelve months from Q2’26

Strong gross profit and healthy liquidity position

Gross Profit
Generated approximately
$127M
in Q2'26

Adj EBITDA[1]
Generated a loss of
$17M
in Q2'26

Liquidity position[2]
Access to
~$190M
As of June 30, 2026

Additional highlights:

Q2'26 adj operating cash outflow[1] was $7.7M

Q2'26 adj free cash outflow[1] was $10.9M

1 GAAP to non-GAAP reconciliations can be found in the Appendix
2 Consists of $115 million of cash and cash equivalents, and availability of additional $75 million under term loan facility

Revising Full-Year 2026 guidance

All figures in millions except percentages

Q3'26 COMMENTARY

Total revenue expected to be at or slightly above Q2'26 total revenue

	FY 2026 FINANCIAL GUIDANCE	FY 2026 COMMENTS
Total Revenue	$770 - $790	Revised the full-year 2026 revenue range lower, reflecting Q2'26 results and current business trends.
Adjusted Gross Margin %*	66% - 67%	This range incorporates the anticipated impact from new product launches

As a result of second quarter 2026 performance and strategic initiatives that are underway, Myriad Genetics is suspending its previous full-year 2026 Adjusted EBITDA guidance and is providing full-year 2026 financial guidance only with respect to Revenue and Adjusted Gross Margin % as set forth above.

Assumes currency rates as of July 30, 2026

* The company does not forecast GAAP gross margin because it cannot predict certain elements that are included in reported GAAP results. See the statement on Non-GAAP Financial Measures at the beginning of this presentation.

Closing Comments

Sam Raha

PRESIDENT &
CHIEF EXECUTIVE OFFICER

Q&A

Appendix

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months Ended June 30, 2026 and 2025 – Adjusted Gross Margin

(unaudited data in millions)

	Three months ended June 30,		Six months ended June 30,	
	2026	**2025**	**2026**	**2025**
Adjusted Gross Margin				
Gross Profit	$ 127.0	$ 151.8	$ 264.6	$ 286.0
Acquisition - amortization of intangible assets(1)	—	0.3	0.1	0.6
Equity compensation(2)	0.5	0.3	0.7	0.6
Other adjustments(3)	—	—	—	0.3
Adjusted Gross Profit	$ 127.5	$ 152.4	$ 265.4	$ 287.5
Adjusted Gross Margin	66.9 %	71.5 %	67.9 %	70.3 %

(1) Represents recurring amortization charges resulting from the acquisition of intangible assets.

(2) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees.

(3) Other one-time non-recurring expenses.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months Ended June 30, 2026 and 2025 – Adjusted Operating Expenses

(unaudited data in millions)

	Three months ended June 30,		Six months ended June 30,	
	2026	2025	2026	2025
Adjusted Operating Expenses				
Operating Expenses	$ 165.9	$ 481.0	$ 334.2	$ 644.2
Acquisition - amortization of intangible assets[1]	(6.4)	(8.1)	(12.8)	(16.9)
Goodwill and long-lived asset impairment[2]	—	(316.7)	(5.4)	(316.7)
Equity compensation[3]	(6.7)	(10.4)	(13.0)	(19.6)
Real estate optimization[4]	—	(2.2)	—	(5.2)
Strategic realignment[5]	(2.3)	(0.1)	(4.0)	(1.8)
Other adjustments[6]	—	0.3	—	0.4
Adjusted Operating Expenses	$ 150.5	$ 143.8	$ 299.0	$ 284.4

Myriad genetics

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months Ended June 30, 2026 and 2025 – Adjusted Operating Expenses (Cont.)

(1) Represents recurring amortization charges resulting from the acquisition of intangible assets.

(2) Expense related to goodwill and long-lived asset impairment. For the six months ended June 30, 2026, consists of $5.4 million of impairment expense associated with our Women's Health reporting unit and certain intangible assets. For the three and six months ended June 30, 2025 consists of $316.7 million of impairment expense associated with our Mental Health and Women's Health reporting units and asset groups.

(3) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees and directors.

(4) Costs related to real estate initiatives. For the three and six months ended June 30, 2025, consists of additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah and South San Francisco, California, while maintaining our current laboratories in those locations and testing and set-up costs for equipment in our new facilities.

(5) Costs related to strategic realignment of the company including severance and consulting fees. Management determined that severance costs that had previously been reported in other one-time expenses should be reported as part of our strategic realignment efforts. Consequently $1.8 million in severance costs that were reported as other adjustments in our reconciliations of GAAP to Non-GAAP financial measures for the six months ended June 30, 2025 were reclassified to strategic realignment in this reconciliation.

(6) Other one-time non-recurring adjustments. See also Note 5 above regarding reclassification of other adjustments to strategic realignment.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months Ended June 30, 2026 and 2025 – Adjusted Net Income (Loss)

(unaudited data in millions, except per share amounts)

	Three months ended June 30,		Six months ended June 30,	
	2026	2025	2026	2025
Adjusted Net Income (Loss)[1]				
Net Loss	$ (43.2)	$ (330.5)	$ (77.3)	$ (330.6)
Acquisition - amortization of intangible assets[2]	6.4	8.4	12.9	17.5
Goodwill and long-lived asset impairment[3]	—	316.7	5.4	316.7
Equity compensation[4]	7.2	10.7	13.7	20.2
Real estate optimization[5]	—	2.2	—	5.2
Strategic realignment[6]	2.3	0.1	4.0	1.8
Other adjustments[7]	—	(0.2)	—	—
Uncertain tax benefit[8]	—	(0.3)	—	(29.0)
Tax adjustments[9]	3.9	(2.3)	9.7	(0.1)
Adjusted Net Income (Loss)	$ (23.4)	$ 4.8	$ (31.6)	$ 1.7
Weighted average shares outstanding:				
Diluted	94.8	92.8	94.2	92.9
Adjusted Income (Loss) Per Share				
Diluted	$ (0.25)	$ 0.05	$ (0.34)	$ 0.02

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months Ended June 30, 2026 and 2025– Adjusted Net Income (Loss) (Cont.)

(1) To determine Adjusted Income (Loss) Per Share.

(2) Represents recurring amortization charges resulting from the acquisition of intangible assets.

(3) Expense related to goodwill and long-lived asset impairment. For the six months ended June 30, 2026, consists of $5.4 million of impairment expense associated with our Women's Health reporting unit and certain intangible assets. For the three and six months ended June 30, 2025, consists of $316.7 million of impairment expense associated with our Mental Health and Women's Health reporting units and asset groups.

(4) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees and directors.

(5) Costs related to real estate initiatives. For the three and six months ended June 30, 2025, consists of additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah and South San Francisco, California, while maintaining our current laboratories in those locations and testing and set-up costs for equipment in our new facilities.

(6) Costs related to strategic realignment of the company including severance and consulting fees. Management determined that severance costs that had previously been reported in other one-time expenses should be reported as part of our strategic realignment efforts. Consequently, $1.8 million in severance costs that were reported as other adjustments in our reconciliations of GAAP to Non-GAAP financial measures for the six months ended June 30, 2025 were reclassified to strategic realignment in this reconciliation.

(7) Other one-time non-recurring adjustments. See also Note 6 above regarding reclassification of certain other adjustments to strategic realignment.

(8) Consists of the release of unrecognized tax benefits and the recognition of valuation allowances for the three and six months ended June 30, 2025. The unrecognized tax benefits released were primarily related to tax years under Joint Committee on Taxation review, which upon conclusion of the review were remeasured or released.

(9) Tax expense or benefit due to non-GAAP adjustments, differences between stock compensation recorded for book purposes as compared to the allowable tax deductions, and valuation allowance recognized against federal and state deferred tax assets in the United States. As of June 30, 2026, a valuation allowance of $118.6 million was not recognized for non-GAAP purposes given our historical and forecasted positive earnings performance. As of June 30, 2025, a valuation allowance of $101.4 million was not recognized for non-GAAP purposes given the company's historical and forecasted positive earnings performance.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months Ended June 30, 2026 and 2025 – Adjusted EBITDA

(unaudited data in millions)

	Three months ended June 30,		Six months ended June 30,	
	2026	**2025**	**2026**	**2025**
Adjusted EBITDA				
Net Loss	$ (43.2)	$ (330.5)	$ (77.3)	$ (330.6)
Acquisition - amortization of intangible assets[(1)]	6.4	8.4	12.9	17.5
Depreciation expense[(2)]	4.8	4.9	9.5	10.0
Goodwill and long-lived asset impairment[(3)]	—	316.7	5.4	316.7
Equity compensation[(4)]	7.2	10.7	13.7	20.2
Real estate optimization[(5)]	—	2.2	—	5.2
Strategic realignment[(6)]	2.3	0.1	4.0	1.8
Interest expense, net of interest income[(7)]	3.7	1.3	7.1	1.8
Other adjustments[(8)]	1.3	0.8	2.7	1.1
Uncertain tax benefits[(9)]	—	(0.3)	—	(29.0)
Income tax (benefit) expense[(10)]	0.6	0.2	0.6	(0.4)
Adjusted EBITDA	$ (16.9)	$ 14.5	$ (21.4)	$ 14.3

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months Ended June 30, 2026 and 2025 – Adjusted EBITDA (Cont.)

(1) Represents recurring amortization charges resulting from the acquisition of intangible assets.

(2) Consists of depreciation expense recognized during the period.

(3) Expense related to goodwill and long-lived asset impairment. For the six months ended June 30, 2026, consists of $5.4 million of impairment expense associated with our Women's Health reporting unit and certain intangible assets. For the three and six months ended June 30, 2025 consists of $316.7 million of impairment expense associated with our Mental Health and Women's Health reporting units and asset groups.

(4) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees and directors.

(5) Costs related to real estate initiatives. For the three and six months ended June 30, 2025, consists of additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah and South San Francisco, California, while maintaining our current laboratories in those locations and testing and set-up costs for equipment in our new facilities.

(6) Costs related to strategic realignment of the company including severance and consulting fees. Management determined that severance costs that had previously been reported in other one-time expenses should be reported as part of our strategic realignment efforts. Consequently $1.8 million in severance costs that were reported as other adjustments in our reconciliations of GAAP to Non-GAAP financial measures for the six months ended June 30, 2025 were reclassified to strategic realignment in this reconciliation.

(7) Derived from interest expense and interest income from the Condensed Consolidated Statements of Operations.

(8) Other one-time non-recurring expenses. For purposes of adjusted EBITDA, this includes Other adjustments described in the Adjusted Net Loss table above as well as the amounts reported as Other income (expense) in the Condensed Consolidated Statement of Operations. See also Note 6 above regarding the reclassification of other adjustments to strategic realignment.

(9) Consists of the release of unrecognized tax benefits and the recognition of valuation allowances for the three and six months ended June 30, 2025. The unrecognized tax benefits released were primarily related to tax years under Joint Committee on Taxation review, which upon conclusion of the review were remeasured or released.

(10) Derived from income tax (benefit) expense from the Condensed Consolidated Statement of Operations, net of the adjustment for unrecognized tax benefits described in Note 9 above.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Six Months Ended June 30, 2026 and 2025 – Adjusted Free Cash Flow

(unaudited data in millions)

	Three months ended June 30,		Six months ended June 30,	
	2026	2025	2026	2025
Adjusted Operating and Free Cash Flow				
Net Cash Used in Operating Activities	$ (8.3)	$ (13.6)	$ (24.0)	$ (29.9)
Real estate optimization[1]	—	3.5	—	7.5
Strategic realignment[2]	0.6	0.1	2.9	1.8
Other adjustments[3]	—	(0.2)	—	—
Adjusted Operating Cash Flow	$ (7.7)	$ (10.2)	$ (21.1)	$ (20.6)
Capital expenditures[4]	(2.1)	(2.8)	(7.5)	(8.1)
Capitalization of internal-use software costs[4]	(1.1)	(4.1)	(2.2)	(7.1)
Adjusted Free Cash Flow	$ (10.9)	$ (17.1)	$ (30.8)	$ (35.8)

(1) The cash flow effect of real estate optimizations, excluding non-cash items such as accelerated depreciation.

(2) Strategic realignment includes the cash paid for those costs in the related periods. During the three and six months ended June 30, 2026, management determined that severance costs that had previously been reported in other one-time expenses should be reported as part of our strategic realignment efforts. Consequently $1.8 million in severance costs that were reported as other adjustments in our reconciliations of GAAP to Non-GAAP financial measures for the six months ended June 30, 2025 were reclassified to strategic realignment in this reconciliation.

(3) The cash flow effect of other one-time non-recurring expenses. See also Note 2 above regarding the reclassification of other adjustments to strategic realignment.

(4) Derived from the Condensed Consolidated Statements of Cash Flows.